Form 4: Puma Biotechnology Executive Sells Shares Under 10b5-1 Plan

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 3,637 shares of common stock at an average price of $3.7011 under a pre-arranged 10b5-1 trading plan.

Summary

• On July 17, 2024, Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 3,637 shares of the company's common stock.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on December 14, 2020.
• The shares were sold at a weighted average price of $3.7011, with individual transaction prices ranging from $3.6001 to $3.8901.
• Following the transaction, Hunt directly owns 133,227 shares of Puma Biotechnology.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the specified range upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-existing 10b5-1 plan, which is a routine transaction.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any inside information at the time of the transaction.

Comparison to Industry Standards

• Executive stock sales are common across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often see similar filings from their executives.
• The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan suggests it was pre-planned and not based on any new information.

Key Dates